Innovative roadmaps for sustainable antimicrobial resistance interventions
Integrated strategies to combat antibiotic-resistant bacteria and fungi require innovative commercial models, new discovery platforms, standardized genomic surveillance, and streamlined clinical trials. Machine learning and other new technologies will accelerate the development of diagnostics and therapeutics (small molecules, antibodies, and vaccines) to combat antimicrobial resistance. Next-generation approaches should align societal impact with investment to ensure rapid global public health gains.
Authors
- J.P. Sevilla (ORCID: https://orcid.org/0000-0001-9807-657X)
- Shiranee Sriskandan (ORCID: https://orcid.org/0000-0002-5214-4941)
- Neil D. Pearson (ORCID: https://orcid.org/0009-0004-2122-2195)
- Anders Karlén (ORCID: https://orcid.org/0000-0001-9512-6981)
- Madalina Elena Carter-Timofte (ORCID: https://orcid.org/0000-0002-1752-2820)
- David Payne
- Francesco Berlanda Scorza (ORCID: https://orcid.org/0000-0003-2307-7855)
- Erin M Duffy (ORCID: https://orcid.org/0000-0002-3319-7554)
- Rosanna Wai Wan Peeling (ORCID: https://orcid.org/0000-0001-7404-8873)
- Darius P. H. Armstrong-James (ORCID: https://orcid.org/0000-0002-1014-7343)
- Sumithra Subramaniam (ORCID: https://orcid.org/0000-0003-0573-4380)
- Jesús Rodríguez-Manzano (ORCID: https://orcid.org/0000-0002-2583-8366)
- Herbert W. Virgin (ORCID: https://orcid.org/0000-0001-8580-7628)
- Philippe Denoël (ORCID: https://orcid.org/0009-0001-9863-6685)
- Alison Holmes (ORCID: https://orcid.org/0000-0001-5554-5743)
- Karen O’Dwyer (ORCID: https://orcid.org/0000-0002-4168-9401)
- Felipe J. Colón‐González (ORCID: https://orcid.org/0000-0002-9671-3405)
- David E. Bloom (ORCID: https://orcid.org/0000-0003-3731-3345)
- Christopher J. Burns (ORCID: https://orcid.org/0000-0002-4463-4916)
- David M. Aanensen (ORCID: https://orcid.org/0000-0001-6688-0854)
- Gianmarco Gasperini (ORCID: https://orcid.org/0000-0001-5411-7667)
- Shampa Das (ORCID: https://orcid.org/0000-0002-2540-4816)
- Ennio De Gregorio (ORCID: https://orcid.org/0000-0002-7706-0162)
- Rino Rappuoli (ORCID: https://orcid.org/0000-0002-8827-254X)
- Michael N. Dudley (ORCID: https://orcid.org/0009-0007-0068-6283)
- Gordon Dougan (ORCID: https://orcid.org/0000-0003-0022-965X)
- Silvia Rossi Paccani
Institutions
- Uppsala University (SE)
- Gates Foundation (US)
- Harvard University (US)
- University of Liverpool (GB)
- Imperial College Healthcare NHS Trust (GB)
- Washington University in St. Louis (US)
- University of Cambridge (GB)
- Novo Nordisk Foundation (DK)
- University of Oxford (GB)
- London School of Hygiene & Tropical Medicine (GB)
- GlaxoSmithKline (Belgium) (BE)
- GlaxoSmithKline (United States) (US)
- Healthcentric Advisors (US)
- GlaxoSmithKline (Italy) (IT)
- Imperial College London (GB)
- Wellcome Trust (GB)
Publication Details
- Journal
- Science Translational Medicine
- Published
- 2026-10-14
- DOI
- https://doi.org/10.1126/scitranslmed.aef8416
- Primary Topic
- Antibiotic Use and Resistance
- Type
- article
- Field-Weighted Citation Impact
- 0.00